osteoarthritis
Allegro shares promising preclinical results for osteoarthritis treatment
March 26, 2025Clinical Trial Services, Research and Development Allegro, Orthopaedics, biomedical, clinical studies, osteoarthritis
Allegro has announced that hydrocelin, its injectable microparticle hydrogel, showed no signs of toxicity in two preclinical studies. Allegro is …
Positive results announced for Levicept’s moderate-to-severe osteoarthritis treatment
August 6, 2024Research and Development Levicept, Rheumatology, osteoarthritis, trial
Biotechnology company Levicept has announced positive results from its phase 2 trial into LEVI-04, for the treatment of osteoarthritis.
Grünenthal receives FDA Breakthrough Therapy Designation for knee osteoarthritis drug
May 23, 2023Medical Communications Breakthrough Therapy Designation, FDA, Grunenthal, Musculo-skeletal disorder, osteoarthritis
German pharmaceutical company Grünenthal has announced that the US Food and Drug Administration (FDA) has awarded it Breakthrough Therapy Designation …
Top Ten most popular articles on Pharmafile.com this week
February 22, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AstraZeneca, Cancer, China, MedImmune, Xeljanz, asthma, diabetes, keytruda, osteoarthritis, pharma, rare disease
Happy Friday! With the weekend within reach, check out our run-down of the top ten most popular articles on Pharmafile.com …
“Game-changing” osteoarthritis drug receives £675k funding from Innovate UK
February 19, 2019Manufacturing and Production, Research and Development AKL Research and Development, Innovate UK, osteoarthritis, pharma
A novel and potentially “game-changing” oral therapy for the treatment of osteoarthritis (OA) has received a £675,000 cash injection from …
Pfizer & Lilly’s non-opioid drug reduces pain in osteoarthritis
October 24, 2018Research and Development Eli Lilly, Pfizer, osteoarthritis, pharma
Pfizer and Eli Lilly have announced data revealing that their nerve growth factor (NGF) inhibitor tanezumab met all three of …
Anika’s osteoarthritis pain drug falls short at Phase 3
June 21, 2018Research and Development Anika Therapeutics, Cingal, osteoarthritis, pharma
Anika Therapeutics has become the latest in a recent string of firms to suffer a failure in a late-stage trial, …
Kitov’s combo gets FDA approval in osteoarthritis and hypertension
June 1, 2018Medical Communications, Sales and Marketing Consensi, FDA, Kitov, US, hypertension, osteoarthritis, pharma
Israeli biopharmaceutical firm is celebrating the approval in the US of Consensi, a combo of the calcium channel blocker amlodipine …
Regeneron and Teva’s experimental drug halted by FDA clinical hold
October 17, 2016Manufacturing and Production Regeneron, Teva, back pain, osteoarthritis
Regeneron Pharmaceuticals and Teva Pharmaceuticals had only just agreed a deal worth a potential $2.6 billion to co-develop Regeneron’s fasinumab …
Teva and Regeneron team up for $2.6 billion pain treatment development
September 21, 2016Research and Development, Sales and Marketing Regeneron, Teva, fasinumab, osteoarthritis
Teva and Regeneron have entered an agreement worth up to $2.6 billion to develop and market the latter’s experimental nerve …
Regeneron says trial drug for osteoarthritis pain meets primary endpoint in Phase II trials
May 3, 2016Manufacturing and Production, Research and Development Phase II, Regeneron Pharmaceuticals, drug trial, osteoarthritis, phase III
Regeneron Pharmaceuticals (Nasdaq: REGN) said mid-stage trials for its drug candidate to treat osteoarthritis pain med its primary endpoint. The …
Flexion Therapeutics announce results for Zilretta trials in osteoarthritis pain
April 5, 2016Manufacturing and Production, Research and Development drugs, flexion, flexion therapeutics, osteoarthritis, pipeline, treatments, zilretta
Flexion Therapeutics has presented positive results from two pivotal clinical trials for its lead drug candidate, Zilretta, which show that …
GSK launches global joint pain education programme
September 13, 2010Medical Communications chronic pain, disease awareness campaigns, osteoarthritis
GlaxoSmithKline has launched a global education programme to help sufferers from musculoskeletal conditions such as arthritis to self-manage pain in …
Stem cell trial for osteoarthritis launched
July 13, 2010Research and Development Arthritis Research UK, Stem cells, osteoarthritis
Stem cell therapy is to be used to treat patients with osteoarthritis in a new UK clinical trial. Medical research …
Latest content
FibroFind appoints Lee Borthwick as CEO
